Dynacure is a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders. The organisation recently opened new offices to house their research and development work. Below, Marion Depla, a Research Scientist at Dynacure writes about the new facilities and the opening event.
Dynacure has recently received Clinical Trial Application (CTA) approval for DYN101, an investigational antisense medicine designed to modulate the expression of Dynamin 2 (DNM2) for the treatment of centronuclear myopathies (CNM). The organisation expect to initiate its first in human study, a Phase 1 / 2 study ‘Unite-CNM’, by the end of 2019.
- Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’
On 23 October, Dynacure officially opened its new laboratories at Bioparc 3 in the Parc d’Innovation, near Strasbourg, France. These facilities will house research and development activities at the cutting edge of clinical stage drug development.
To highlight this occasion, Chief Executive Officer (CEO), Stéphane Van Rooijen and Dynacure Chairman, Georges Gemayel symbolically planted the first sunflower seeds in the presence of the Strasbourg scientific community, local officials and key collaborators and investors.
Dynacure is honoured to be part of the 20th year of The Big Sunflower Project, led by Toni Abram. We are grateful to Toni and the CNM patient community and are committed to raising awareness of centronuclear and myotubular myopathies.